@article{40186f514bd94d18a44fcf3171d14b2f,
title = "Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia",
abstract = "BACKGROUND: Patients with acute myeloid leukemia (AML) receiving intensive chemotherapy face a life-threatening illness, isolating hospitalization, and substantial physical and psychological symptoms. However, data are limited regarding risk factors of posttraumatic stress disorder (PTSD) symptoms in this population. METHODS: The authors conducted a secondary analysis of data from 160 patients with high-risk AML who were enrolled in a supportive care trial. The PTSD Checklist-Civilian Version was used to assess PTSD symptoms at 1 month after AML diagnosis. The Brief COPE and the Functional Assessment of Cancer Therapy-Leukemia were to assess coping and quality of life (QOL), respectively. In addition, multivariate regression models were constructed to assess the relation between PTSD symptoms and baseline sociodemographic factors, coping, and QOL. RESULTS: Twenty-eight percent of patients reported PTSD symptoms, describing high rates of intrusion, avoidance, and hypervigiliance. Baseline sociodemographic factors significantly associated with PTSD symptoms were age (B = −0.26; P =.002), race (B = −8.78; P =.004), and postgraduate education (B = −6.30; P =.029). Higher baseline QOL (B = −0.37; P ≤.001) and less decline in QOL during hospitalization (B = −0.05; P =.224) were associated with fewer PTSD symptoms. Approach-oriented coping (B = −0.92; P =.001) was associated with fewer PTSD symptoms, whereas avoidant coping (B = 2.42; P ≤.001) was associated with higher PTSD symptoms. CONCLUSIONS: A substantial proportion of patients with AML report clinically significant PTSD symptoms 1 month after initiating intensive chemotherapy. Patients' baseline QOL, coping strategies, and extent of QOL decline during hospitalization emerge as important risk factors for PTSD, underscoring the need for supportive oncology interventions to reduce the risk of PTSD in this population.",
keywords = "acute leukemia, coping, distress, hematologic malignancy, hypervigilance, posttraumatic stress, posttraumatic stress disorder, psychological well-being, traumatic stress",
author = "Amonoo, {Hermioni L.} and LeBlanc, {Thomas W.} and Kavanaugh, {Alison R.} and Webb, {Jason A.} and Traeger, {Lara N.} and Jagielo, {Annemarie D.} and Vaughn, {Dagny M.} and Madeleine Elyze and Longley, {Regina M.} and Fathi, {Amir T.} and Hobbs, {Gabriela S.} and Brunner, {Andrew M.} and O{\textquoteright}Connor, {Nina R.} and Luger, {Selina M.} and Gustin, {Jillian L.} and Bhavana Bhatnagar and Horick, {Nora K.} and Areej El-Jawahri",
note = "Funding Information: Hermioni L. Amonoo reports grants from the National Cancer Institute, during the conduct of the study. Thomas W. Leblanc reports grants from the American Cancer Society, Duke University, National Institute of Nursing Research/National Institutes of Health, Jazz Pharmaceuticals, and Seattle Genetics; personal fees from AbbVie, Agios, Amgen, AstraZeneca, Bristol Myers Squibb, CareVive, Daiichi-Sankyo, Flat Iron, Helsinn, Heron, Medtronic, Otsuka, Pfizer, Seattle Genetics, and Welvie; and royalties received from UpToDate, outside the submitted work. Amir T. Fathi reports clinical trial support from Exelexis; clinical trial support and personal fees from Agios, Celgene/Bristol Myers Squibb, and Takeda; and personal fees from Boston Biomedical and Jazz Pharmaceuticals, outside the submitted work. Gabriela Hobbs reports personal fees from AbbVie, Celgene/Bristol Myers Squibb, Constellation, and Novartis, outside the submitted work. Andrew Brunner reports grants from the Dana-Farber/Harvard Cancer Center Leukemia Specialized Programs of Research Excellence and the Evans Foundation; institutional clinical trial support and personal fees from AstraZeneca, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Jazz Pharmaceuticals, Novartis, and Takeda; and personal fees from Agios, Biogen, Forty Seven Inc, and Xcenda, outside the submitted work. Bhavana Bhatnagar reports research support from Cell Therapeutics and Karyopharm Therapeutics; and personal fees from Astellas, Celgene, Cell Therapeutics, Kite Pharma, Novartis, and Pfizer, outside the submitted work. The remaining authors made no disclosures. Time for analysis and article preparation was supported by the National Cancer Institute through grant K08CA251654 (to Dr. Amonoo). Publisher Copyright: {\textcopyright} 2021 American Cancer Society",
year = "2021",
month = jul,
day = "15",
doi = "10.1002/cncr.33524",
language = "English (US)",
volume = "127",
pages = "2500--2506",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "14",
}